Education
About Us
Working with TipRanks
Follow Us
Accolade, Inc. (ACCD)
NASDAQ:ACCD
ACCD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.08 - $9.67
Previous CloseN/A
Volume14.97M
Average Volume (3M)1.27M
Market Cap
$575.59M
Enterprise Value$323.71M
Total Cash (Recent Filing)$321.08M
Total Debt (Recent Filing)$317.39M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Apr 24, 2025EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.25
Shares Outstanding47,285,000
10 Day Avg. Volume1,132,264
30 Day Avg. Volume1,266,764
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.28
Price to Cash Flow (P/CF)-14.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.69
Enterprise Value/Ebitda-7.10
Forecast
1Y Price Target
$7.03Price Target Upside0.14% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Accolade News
PremiumCompany Announcements
Accolade Completes Merger, Plans Nasdaq Delisting
PremiumCompany Announcements
Accolade Stockholders Approve Merger with Transcarent
---
Bulls Say, Bears Say
Bulls Say
AcquisitionThe acquisition by Transcarent represents a premium of approximately 110% compared to the previous closing price.
Scale And ResourcesThe combined entity is expected to benefit from incremental scale and complementary technology/service resources.
Strategic BenefitsThe strategic acquisition is seen as logical and synergistic, enhancing AI capabilities in ACCD's operations.
Bears Say
Guidance WithdrawalThe company is withdrawing its prior guidance for FY25 and will not host the previously scheduled call.
Revenue ForecastFY25 revenue is projected at $441.7M vs. guidance calling for $467.5M at the midpoint.
Stock DowngradeA competing bid is less likely, leading to a downgrade from Buy to Hold and a price target reduction to $7.03.
---
Ownership Overview
9.82% Insiders
16.65% Mutual Funds
31.81% Other Institutional Investors
74.87% Public Companies and
Individual Investors
ACCD FAQ
What was Accolade, Inc.’s price range in the past 12 months?
Accolade, Inc. lowest stock price was $3.08 and its highest was $9.67 in the past 12 months.
What is Accolade, Inc.’s market cap?
Accolade, Inc.’s market cap is $575.59M.
When is Accolade, Inc.’s upcoming earnings report date?
Accolade, Inc.’s upcoming earnings report date is Apr 24, 2025 which is 6 days ago.
How were Accolade, Inc.’s earnings last quarter?
Accolade, Inc. released its earnings results on Jan 09, 2025. The company reported -$1.5 earnings per share for the quarter, missing the consensus estimate of -$0.324 by -$1.176.
Is Accolade, Inc. overvalued?
According to Wall Street analysts Accolade, Inc.’s price is currently Undervalued.
Does Accolade, Inc. pay dividends?
Accolade, Inc. does not currently pay dividends.
What is Accolade, Inc.’s EPS estimate?
Accolade, Inc.’s EPS estimate is 0.05.
How many shares outstanding does Accolade, Inc. have?
Accolade, Inc. has 47,285,000 shares outstanding.
What happened to Accolade, Inc.’s price movement after its last earnings report?
Accolade, Inc. reported an EPS of -$1.5 in its last earnings report, missing expectations of -$0.324. Following the earnings report the stock price went up 1.763%.
Which hedge fund is a major shareholder of Accolade, Inc.?
Currently, no hedge funds are holding shares in ACCD
---
Accolade Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$7.03 (0.14% Upside)
$7.03 (0.14% Upside)
Blogger Sentiment
Bullish
ACCD Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 478.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.5%
Last 30 Days ▼ 9.5%
Last 30 Days ▼ 9.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.12%
12-Months-Change
Fundamentals
Return on Equity
-48.23%
Trailing 12-Months
Asset Growth
-17.57%
Trailing 12-Months
Company Description
Accolade, Inc.
Accolade, Inc. (ACCD) is a healthcare technology company that provides personalized health and benefits solutions for employers and health plans. The company operates in the health services sector, offering a platform that combines technology and human expertise to assist individuals in navigating the complex healthcare system. Accolade's core services include health advocacy, navigation, and virtual healthcare services, which aim to improve healthcare outcomes and reduce costs for clients.
---
ACCD Company Deck
---
ACCD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Accolade reported strong revenue and cash flow performance, with significant new wins and a robust cash position. However, challenges include potential delays in health plan deployments and increased pressure from ROI guarantees.Read More>---
ACCD Stock 12 Month Forecast
Average Price Target
$7.03
▲(0.14% Upside)
Technical Analysis
AnaptysBio
―
Organogenesis Holdings
―
Castle Biosciences
―
Maravai Lifesciences Holdings
―
Tyra Bioscience
―
---